GH Research (GHRS) Loans - Gross (2024 - 2025)
GH Research (GHRS) posted quarterly Loans - Gross of $2.3 million for Q4 2025, down 93.38% year-over-year from $34.0 million in Q4 2024, and down 93.38% quarter-over-quarter from $34.0 million in Q4 2024.
GH Research (GHRS) Loans - Gross (2024 - 2025) Analysis & Trends
GH Research's Loans - Gross history runs 2 years deep, the most recent figure standing at $2.3 million for Q4 2025.
- In Q4 2025, Loans - Gross fell 93.38% year-over-year to $2.3 million; the TTM figure through Dec 2025 stood at $2.3 million (down 93.38% YoY), while the FY2025 annual figure was $2.3 million, down 93.38% from the prior year.
- Loans - Gross for Q4 2025 stood at $2.3 million, down from $34.0 million in the prior quarter.
- The five-year high for Loans - Gross was $34.0 million in Q4 2024, with the low at $2.3 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Loans - Gross (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | GH Research | 2.02 Bn | 1.68 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.25 Mn |
| Dec 31, 2024 | 34.05 Mn |